Veradermics is trading at $127.66, up 4.40%, with biotech-sector strength the clearest same-direction context; XBI is up 2.10% during the regular session. - On October 19, Veradermics announced positive Phase 3 Study 304 results, meeting primary and secondary endpoints. - Available reporting does not identify those results as the direct cause of the October 20 move; no specific October 20 company catalyst was identified.